deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03860935

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial)

Sponsor: Eidos Therapeutics, a BridgeBio company

Conditions Amyloid Cardiomyopathy Amyloidosis Cardiomyopathies Heart Diseases Transthyretin Amyloidosis
Interventions Placebo Oral Tablet acoramidis
Updated 26 times since 2019 Last updated: Jun 5, 2024 Started: Mar 19, 2019 Primary completion: May 11, 2023 Completion: May 11, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Amyloid Cardiomyopathy and Amyloidosis, this trial is completed. The trial is conducted by Eidos Therapeutics, a BridgeBio company and has accumulated 26 data snapshots since 2019. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Aug 2023 · 19 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 4 months · monthly snapshot

Change History

26 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Feb 2026 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 21 earlier versions

  1. Jan 2022 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

  3. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Oct 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  7. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  8. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  9. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  10. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE3

  11. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE3

  12. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

  13. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  14. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE3

  15. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  16. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  17. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  18. Jul 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  19. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  20. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  21. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

    First recorded

Mar 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eidos Therapeutics, a BridgeBio company
Data source: Eidos Therapeutics, a BridgeBio company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Aarhus, Denmark , Adelaide, Australia , Arezzo, Italy , Athens, Greece , Athens, United States , Atlanta, United States , Aurora, United States , Baltimore, United States , Barcelona, Spain and 81 more locations